UPDATE: Endogenex Announces Full Enrollment of the ReCET Clinical Study

Trial StartReCETPositive

AI Analysis

Summary

Endogenex announced full enrollment of 350 patients in the ReCET clinical study across U.S. and Australian sites for a novel endoscopic treatment of Type 2 Diabetes, progressing toward FDA approval.

Clinical Trial Data

Patients

350

Outcome Details

Full enrollment of 350 patients completed

Importance:5/10

Sentiment:

0.60

clinical trialenrollmentendoscopic treatmentType 2 DiabetesFDA approval pathway

Related Companies

$UTHR

Read the original article

Published by GlobeNewswire Clinical Studies on July 8, 2026 8:10 PM

Read Original